Actionable Consent Data Helps Client Save an Estimated $100M

During a large pharmaceutical company's Phase I and Phase II trials for an early stage Alzheimer's disease drug development program, patients had a skin reaction reported as a severe adverse event (SAE) that was considered to be market-limiting for the compound. Due to having specimen collection tracked in real time, the company was able to quickly ensure that there would be broad consent for additional testing of patient specimens to determine genetic association. This enabled a faster no-go decision, saving an estimated $100 million, which would have been spent on a Phase III trial that would have had a low probability of success before it even began.